NCT01932125 - An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions

Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms

Interventions

DRUG

Bevacizumab

Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.

Trial Locations (13)

110085

Rajiv Gandhi Cancer Inst.&Research Center, New Delhi

110092

MAX Balaji Hospital, Delhi

400056

MOC Cancer Care & Research Centre, Mumbai

411001

Grant Medical Foundation, Ruby Hall Clinic, Pune

Jehangir Clinical Development Centre Pvt. Ltd, Pune

411004

Sahyadri Speciality Hospital, Pune

422002

HCG Manavata Cancer Centre, Nashik

422009

Apex Wellness Hospital, Nashik

431001

Marthwada Regional Cancer Center & Research Institute, Aurangabad

440026

HCG NCHRI Cancer Center, Nagpur

560017

Manipal Hospital, Bangalore

560027

HealthCare Global Enterprises Limited, Banglore

700094

Peerless Hospitex Hospital and Research Center Ltd., Kolkata

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY